The U.S. drug pricing landscape is undergoing a fundamental transformation.
Historically insulated from international reference pricing, new policy developments, such as the emergence of TrumpRx and Most Favored Nation (MFN) dynamics, are dismantling traditional benchmarks. Instead of relying on a single, consistent reference point, life sciences organizations must now navigate a complex, globally interconnected web of pricing signals.
With multiple datasets in play ranging from list and net prices to channel-specific variations and GDP-adjusted affordability contexts, assessing your true pricing position has never been more challenging.
When pricing, access, and policy teams are forced to evaluate these elements in isolation, it inevitably leads to inconsistent interpretations, misaligned internal narratives, and delayed decision-making in a critical market.
Are your current strategies equipped to handle this multifaceted reality?
Discover how to connect these disparate insights and navigate this new era of pricing complexity with confidence through a unified pricing intelligence framework built to protect your strategic advantage.
Download the Article
Author
Andrew is responsible for EVERSANA’s International pharmaceutical price database, NAVLIN Price & Access Data. He oversees a team of more than 50 people across the U.S., Europe, and India. With more than 15+ years…
Vinod Bombale is a Product Manager at EVERSANA, where he drives the development of the NAVLIN data product within the pharmaceutical pricing and market access space. With over 12 years of experience, he brings strong…